PedAM
Pediatric Disease Annotations & Medicines
| Disease | liver disease |
| Symptom | |diabetes |
| Sentences | 69 |
| PubMedID- 26441826 | Management of diabetes in patients with liver diseases is, however, complicated by the effects of drug metabolism by the liver, drug interactions, and potential liver toxicity of some medications used to treat diabetes for review, see ref. |
| PubMedID- 26398404 | *adjusted for: age at hcc diagnosis; sex; rural residence; income quintile; charlson-deyo comorbidity index; diabetes diagnosis; indicators of severe liver disease: no alcoholic liver disease (ald)+no cirrhosis; no ald+cirrhosis only; no ald+decompensated cirrhosis; ald+no cirrhosis; ald+cirrhosis; ald+decompensated cirrhosis; non-alcoholic fatty liver disease (nafld)+cirrhosis; and index year of hepatocellular carcinoma (hcc) diagnosis. |
| PubMedID- 22201932 | Non alcoholic fatty liver disease (nafld) is associated with obesity, diabetes and insulin resistance (ir). |
| PubMedID- 26116622 | In addition, we describe recent findings regarding the role of fgf21 in the pathogenesis and treatment of diabetes associated with obesity, liver diseases, pancreatitis, muscle atrophy, atherosclerosis, cardiac hypertrophy, and diabetic nephropathy. |
| PubMedID- 21642744 | Akr1b7 may be a therapeutic target for treatment of fatty liver disease associated with diabetes mellitus. |
| PubMedID- 19758274 | By multivariate analysis, age > or = 65 years, alcohol consumption and diabetes were independently associated with advanced liver disease. |
| PubMedID- 25820927 | Patients were excluded from the study if they had type 1 diabetes, a history of ketoacidosis, active liver disease, significant and active cardiovascular disease, malignancy, hematological disorders or hyperthyroidism. |
| PubMedID- 20096896 | Recent evidence has suggested an association between microalbuminuria and ultrasound-diagnosed nonalcoholic fatty liver disease (nafld) in patients with diabetes and prediabetes. |
| PubMedID- 26322515 | As shown earlier, elevated ggt levels are considered a marker for non-alcoholic fatty liver disease and are associated with diabetes, arterial hypertension and cardiovascular diseases , . |
| PubMedID- 26339423 | Prognostic value of high sensitivity c-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease. |
| PubMedID- 23043895 | Fatty liver disease is epidemiologically associated with type 2 diabetes (t2d), leading to a speculation of a reciprocal cause-effect relationship and a vicious cycle of pathology. |
| PubMedID- 26274925 | Comorbidities examined in this study included acquired immunodeficiency syndrome (aids), cardiovascular disease (cad), cerebrovascular disease (cvd), mild diabetes, diabetes with complications, liver disease, primary malignancy, metastatic malignancy, and renal disease. |
| PubMedID- 25829790 | Background: insulin resistance (ir) is amalgam of pathologies like altered glucos metabolism, dyslipidemia, impaired glucose tolerance, non-alcoholic fatty liver disease, and associated with type-ii diabetes and cardiometabolic diseases. |
| PubMedID- 26147768 | Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus. |
| PubMedID- 25140521 | Context: both longer habitual day napping and non-alcoholic fatty liver disease (nafld) are associated with diabetes and inflammation, but the association between day napping and nafld remains unexplored. |
| PubMedID- 26509504 | Various liver diseases are associated with diabetes . |
| PubMedID- 26198953 | Objective: to investigate the association of serum pigment epithelium-derived factor (pedf) level and polymorphisms in pedf gene promoter region -358g-->a with non-alcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (t2dm) of han nationality in fujian province. |
| PubMedID- 25877002 | The aggravation of mitochondrial dysfunction in nonalcoholic fatty liver disease accompanied with type 2 diabetes mellitus. |
| PubMedID- 23489256 | Aim: the aim of this case-control study was to assess the efficacy and safety of dipeptidyl peptidase-4 inhibitor (sitagliptin) for type 2 diabetes mellitus (t2dm) with non-alcoholic fatty liver disease (nafld). |
Page: 1 2